Paul Tudor Jones Cure Vac N.V. Transaction History

Tudor Investment Corp Et Al

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.94 - $4.34 $6,503 - $9,600	-2,212 Reduced 18.01%	10,070 $30,000
Q4 2023 Feb 14, 2024	BUY	$3.96 - $6.41 $48,636 - $78,727	12,282 New	12,282 $51,000
Q2 2023 Aug 14, 2023	BUY	$6.69 - $12.25 $143,527 - $262,811	21,454 New	21,454 $223,000
Q4 2022 Feb 14, 2023	BUY	$5.75 - $8.5 $84,881 - $125,477	14,762 New	14,762 $89,000
Q2 2022 Aug 15, 2022	BUY	$13.18 - $19.41 $126,897 - $186,879	9,628 Added 75.77%	22,335 $304,000
Q1 2022 May 16, 2022	BUY	$14.73 - $35.25 $50,082 - $119,850	3,400 Added 36.53%	12,707 $249,000
Q4 2021 Feb 14, 2022	BUY	$33.72 - $48.22 $313,832 - $448,783	9,307 New	9,307 $319,000
Q3 2021 Nov 15, 2021	SELL	$49.26 - $74.5 $146,400 - $221,414	-2,972 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$56.91 - $127.53 $3,357 - $7,524	-59 Reduced 1.95%	2,972 $218,000
Q1 2021 May 17, 2021	BUY	$79.79 - $126.29 $241,843 - $382,784	3,031 New	3,031 $277,000

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $514M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.